Trial Outcomes & Findings for Trial of TRC105 and Sorafenib in Patients With HCC (NCT NCT02560779)

NCT ID: NCT02560779

Last Updated: 2020-07-17

Results Overview

If 1 of 3 patients experienced a DLT, the dose level was expanded to 6 patients. The maximum tolerated dose (MTD) would have been exceeded if ≥ 33% of patients experience DLT at a given dose level. DLT occurred when a patient had 1 or more toxicities outlined in the protocol that was considered at least possibly related to TRC105 during the first 4 months of participation in the trial. The number of DLTs by dose cohort have been presented.

• Recruitment status: COMPLETED
• Study phase: PHASE1/PHASE2
• Target enrollment: 27 participants
• Primary outcome timeframe: 4 months
• Results posted on: 2020-07-17

Participant Flow

Participant milestones

Measure	Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib Carotuximab (TRC105) given weekly (10 mg/kg) for 2 cycles then bi-weekly iv TRC105 (15 mg/kg) with 400mg sorafenib twice daily	Carotuximab (10 mg/kg Weekly) Plus Sorafenib Carotuximab (TRC105) given weekly iv (10 mg/kg) with 400mg sorafenib twice daily
Overall Study STARTED	14	13
Overall Study COMPLETED	14	13
Overall Study NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Trial of TRC105 and Sorafenib in Patients With HCC

Baseline characteristics by cohort

Measure	Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib n=14 Participants Carotuximab (TRC105) given weekly (10 mg/kg) for 2 cycles then bi-weekly iv TRC105 (15 mg/kg) with 400mg sorafenib twice daily	Carotuximab (10 mg/kg Weekly) Plus Sorafenib n=13 Participants Carotuximab (TRC105) given weekly iv (10 mg/kg) with 400mg sorafenib twice daily	Total n=27 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	6 Participants n=5 Participants	6 Participants n=7 Participants	12 Participants n=5 Participants
Age, Categorical >=65 years	8 Participants n=5 Participants	7 Participants n=7 Participants	15 Participants n=5 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	4 Participants n=7 Participants	4 Participants n=5 Participants
Sex: Female, Male Male	14 Participants n=5 Participants	9 Participants n=7 Participants	23 Participants n=5 Participants
Race/Ethnicity, Customized Asian	2 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants
Race/Ethnicity, Customized White	9 Participants n=5 Participants	7 Participants n=7 Participants	16 Participants n=5 Participants
Race/Ethnicity, Customized Black or African American	2 Participants n=5 Participants	5 Participants n=7 Participants	7 Participants n=5 Participants
Race/Ethnicity, Customized Unknown	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants
Region of Enrollment United States	14 participants n=5 Participants	13 participants n=7 Participants	27 participants n=5 Participants

PRIMARY outcome

Timeframe: 4 months

Population: Patients must have received at least a portion of a dose of TRC105 or sorafenib to be evaluable for assessment of DLT.

If 1 of 3 patients experienced a DLT, the dose level was expanded to 6 patients. The maximum tolerated dose (MTD) would have been exceeded if ≥ 33% of patients experience DLT at a given dose level. DLT occurred when a patient had 1 or more toxicities outlined in the protocol that was considered at least possibly related to TRC105 during the first 4 months of participation in the trial. The number of DLTs by dose cohort have been presented.

Outcome measures

Measure	Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib n=14 Participants Carotuximab (TRC105) given weekly (10 mg/kg) for 2 cycles then bi-weekly iv TRC105 (15 mg/kg) with 400mg sorafenib twice daily	Carotuximab (10 mg/kg Weekly) Plus Sorafenib n=13 Participants Carotuximab (TRC105) given weekly iv (10 mg/kg) with 400mg sorafenib twice daily
Number of Patients Who Experience Dose Limiting Toxicities by Dose Level	1 Participants	0 Participants

PRIMARY outcome

Timeframe: 4 months

Population: Patients must have had a screening scan and at least 1 on study scan to be eligible for RECIST 1.1 evaluation.

Number of patients with a response (PR or CR) are included by dose level. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Patients must have had a screening scan and at least 1 on study scan to be eligible for RECIST 1.1 evaluation.

Outcome measures

Measure	Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib n=14 Participants Carotuximab (TRC105) given weekly (10 mg/kg) for 2 cycles then bi-weekly iv TRC105 (15 mg/kg) with 400mg sorafenib twice daily	Carotuximab (10 mg/kg Weekly) Plus Sorafenib n=11 Participants Carotuximab (TRC105) given weekly iv (10 mg/kg) with 400mg sorafenib twice daily
Overall Response Rate (ORR)	2 Participants	1 Participants

SECONDARY outcome

Timeframe: 5 weeks

Population: Steady state mean trough serum concentration by dose level after 5 weeks of dosing. Patients must have received all protocol required TRC105 doses to be included in the analysis. Additional analysis were not performed as TRC105 development overall was canceled due to lack of efficacy.

Steady state mean trough serum concentrations by dose level of TRC105 after 5 weeks of dosing were measured using validated methods after 5 weeks of dosing.

Outcome measures

Measure	Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib n=8 Participants Carotuximab (TRC105) given weekly (10 mg/kg) for 2 cycles then bi-weekly iv TRC105 (15 mg/kg) with 400mg sorafenib twice daily	Carotuximab (10 mg/kg Weekly) Plus Sorafenib n=3 Participants Carotuximab (TRC105) given weekly iv (10 mg/kg) with 400mg sorafenib twice daily
Pharmacokinetic Profile of TRC105 When Given With Sorafenib	14.2 ug/ML Standard Deviation 12.1	44.7 ug/ML Standard Deviation 9

SECONDARY outcome

Timeframe: 19 months

Population: Number of patients who tested positive for antibodies to TRC105. Patients must have tested negative for TRC105 antibodies at baseline and have had an on study test performed to be included in the analysis.

Number of patients who tested positive for antibodies to TRC105 by dose level. Anti-Product Antibody (APA) concentrations were measured using validated ELISA methods.

Outcome measures

Measure	Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib n=13 Participants Carotuximab (TRC105) given weekly (10 mg/kg) for 2 cycles then bi-weekly iv TRC105 (15 mg/kg) with 400mg sorafenib twice daily	Carotuximab (10 mg/kg Weekly) Plus Sorafenib n=5 Participants Carotuximab (TRC105) given weekly iv (10 mg/kg) with 400mg sorafenib twice daily
TRC105 Immunogenicity as Assessed by Anti-Product Antibody (APA)	9 Participants	5 Participants

Adverse Events

Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib

Serious events: 5 serious events

Other events: 14 other events

Deaths: 0 deaths

Carotuximab (10 mg/kg Weekly) Plus Sorafenib

Serious events: 9 serious events

Other events: 13 other events

Deaths: 0 deaths

Serious adverse events

Measure	Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib n=14 participants at risk Carotuximab (TRC105) given weekly (10 mg/kg) for 2 cycles then bi-weekly iv TRC105 (15 mg/kg) with 400mg sorafenib twice daily	Carotuximab (10 mg/kg Weekly) Plus Sorafenib n=13 participants at risk Carotuximab (TRC105) given weekly iv (10 mg/kg) with 400mg sorafenib twice daily
Renal and urinary disorders Acute kidney injury	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Alanine Aminotransferase Increased	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Blood and lymphatic system disorders Anemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Aspartate Aminotransferase Increase	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Blood Bilirubin Increased	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Cardiac disorders Cardiac Failure	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Hepatobiliary disorders Cholangitis	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Dyspnoea	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Encephalopathy	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Epstaxis	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Haemorrhage Intracranial	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Vascular disorders Hypotension	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Ileus	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Injury, poisoning and procedural complications Infusion Related Reaction	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to Central Nervous System	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Nausea	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Oesophageal Haemorrhage	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Pancreatitis	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Pleural Effusion	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Rectal Haemorrhage	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Respiratory Failure	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Upper Gastrointestinal Haemorrhage	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Vomiting	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Wound Infection	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.

Other adverse events

Measure	Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib n=14 participants at risk Carotuximab (TRC105) given weekly (10 mg/kg) for 2 cycles then bi-weekly iv TRC105 (15 mg/kg) with 400mg sorafenib twice daily	Carotuximab (10 mg/kg Weekly) Plus Sorafenib n=13 participants at risk Carotuximab (TRC105) given weekly iv (10 mg/kg) with 400mg sorafenib twice daily
Gastrointestinal disorders Abdominal Pain	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	38.5% 5/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Abdominal Distension	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Abdominal Pain Lower	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Abdominal Pain Upper	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Renal and urinary disorders Acute Kidney Injury	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Psychiatric disorders Agitation	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Alanine Aminotransferase Increased	21.4% 3/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	30.8% 4/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Alopecia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Ammonia Increased	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Blood and lymphatic system disorders Anemia	42.9% 6/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	46.2% 6/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Angioedema	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Psychiatric disorders Anxiety	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Arthralgia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Injury, poisoning and procedural complications Arthropod Bite	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Ascites	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Aspartate Aminotransferase Increased	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	30.8% 4/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Aspiration	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Asthenia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Ataxia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Cardiac disorders Atrial Fibrillation	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Back Pain	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Bacteraemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Hepatobiliary disorders Bile Duct Obstruction	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Blood Alkaline Phosphatase Increased	21.4% 3/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	30.8% 4/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Blood Amylase Increased	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	23.1% 3/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Blood Bilirubin Increased	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	30.8% 4/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Blood Blister	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Blood Creatinine Increased	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Blood Phosphorus Decreased	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Cardiac disorders Bradycardia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Bronchitis	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Cardiac disorders Cardiac Failure	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Cellulitis	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Chest Pain	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Chills	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	53.8% 7/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Hepatobiliary disorders Cholelithiasis	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Chronic Obstructive Pulmonary Disease	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Psychiatric disorders Confusional State	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	23.1% 3/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Constipation	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	46.2% 6/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Injury, poisoning and procedural complications Contusion	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Cardiac disorders Coronary Artery Disease	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Cough	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	23.1% 3/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Decreased Appetite	35.7% 5/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	53.8% 7/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Dehydration	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Psychiatric disorders Depression	21.4% 3/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Dermatitis Acneiform	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Device Related Infection	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Diarrhoea	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	69.2% 9/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Dizziness	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	23.1% 3/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Immune system disorders Drug Hypersensitivity	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Dry Mouth	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Dry Skin	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Dysarthria	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Dysgeusia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Dysphagia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Dysphonia	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Dyspnoea	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	38.5% 5/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Dyspnoea Exertional	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Renal and urinary disorders Dysuria	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Encephalopathy	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Epistaxis	64.3% 9/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	84.6% 11/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Eye disorders Eye Pain	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Faeces Discoloured	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Injury, poisoning and procedural complications Fall	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	23.1% 3/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Fatigue	50.0% 7/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	100.0% 13/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Flank Pain	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Vascular disorders Flushing	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Frequent Bowel Movements	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Gait Disturbance	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Gastritis	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Gastrooesophageal Reflux Disease	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	23.1% 3/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Gingival Bleeding	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	38.5% 5/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Glossodynia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Gout	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Groin Pain	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Haematemesis	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Haematochezia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Renal and urinary disorders Haematuria	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Haemorrhoids	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Headache	42.9% 6/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	84.6% 11/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hyperammonaemia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hypercalcaemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hyperglycaemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Hyperhidrosis	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hyperkalaemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Vascular disorders Hypertension	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	61.5% 8/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Hypoaesthesia Oral	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hypoalbuminaemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hypocalcaemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hypokalaemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hypomagnesaemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hyponatraemia	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Hypophosphataemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Vascular disorders Hypotension	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Endocrine disorders Hypothyroidism	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Injury, poisoning and procedural complications Infusion Related Reaction	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	30.8% 4/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Psychiatric disorders Insomnia	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations International Normalised Ratio Increased	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Irritability	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Joint Effusion	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Injury, poisoning and procedural complications Laceration	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Lactic Acidosis	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Lip Swelling	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Lipase Increased	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	30.8% 4/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung Squamous Cell Carcinoma Stage Unspecified	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Malaise	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Medical Device Site Bruise	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Melaena	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Blood and lymphatic system disorders Microcytic Anaemia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Mouth Haemorrhage	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Mucosal Inflammation	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Muscle Spasms	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	23.1% 3/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Muscular Weakness	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Musculoskeletal Chest Pain	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Myalgia	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Nasal Congestion	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Nausea	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	38.5% 5/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Neuropathy Peripheral	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Neutrophil Count Decreased	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Non-Cardiac Chest Pain	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Odynophagia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Oedema Peripheral	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	23.1% 3/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Oropharyngeal Blistering	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain	28.6% 4/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Pain in Extremity	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Pain in Jaw	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Palmar-Plantar Erythrodysaesthesia Syndrome	42.9% 6/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	61.5% 8/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Paraesthesia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Paraplegia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Periodontal Disease	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Peripheral Sensory Neuropathy	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Eye disorders Photopsia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Photosensitivity Reaction	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Platelet Count Decreased	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Pleural Effusion	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	23.1% 3/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Pleuritic Pain	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Pneumonia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Renal and urinary disorders Pollakiuria	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Renal and urinary disorders Polyuria	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Hepatobiliary disorders Portal Vein Thrombosis	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Proctalgia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Productive Cough	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Renal and urinary disorders Proteinuria	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Pruritus	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Pulmonary Embolism	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Purpura	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
General disorders Pyrexia	35.7% 5/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	30.8% 4/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Rash	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	30.8% 4/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Rash Maculo-Papular	35.7% 5/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Rectal Haemorrhage	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Rectal Ulcer	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Psychiatric disorders Restlessness	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Musculoskeletal and connective tissue disorders Rhabdomyolysis	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Rhinalgia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Rhinitis Allergic	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Scrotal Infection	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Seborrhoeic Dermatitis	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Sinus Congestion	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Cardiac disorders Sinus Tachycardia	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Sinusitis	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Skin Abrasion	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Skin Discolouration	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Skin Lesion	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Skin Papilloma	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Skin Ulcer	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Spinal Cord Compression	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Stomatitis	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Subcutaneous Abscess	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Cardiac disorders Tachycardia	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Telangiectasia	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Reproductive system and breast disorders Testicular Swelling	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Injury, poisoning and procedural complications Thermal Burn	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Ear and labyrinth disorders Tinnitus	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Tooth Abscess	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Tremor	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Upper Gastrointestinal Haemorrhage	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Upper Respiratory Infection	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Upper-Airway Cough Syndrome	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Renal and urinary disorders Urinary Hesitation	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Infections and infestations Urinary Tract Infection	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Skin and subcutaneous tissue disorders Urticaria	7.1% 1/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	0.00% 0/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Nervous system disorders Viith Nerve Paralysis	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Eye disorders Vision Blurred	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Metabolism and nutrition disorders Vitamin D Deficiency	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Gastrointestinal disorders Vomiting	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Weight Decreased	14.3% 2/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	23.1% 3/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations Weight Increased	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	15.4% 2/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.
Investigations White Blood Cell Count Decreased	0.00% 0/14 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.	7.7% 1/13 • Adverse events were collected while on study and for 28 days following the last dose of TRC105 or sorafenib. The longest duration of participation of any patient on study was 24 months. Only patients who received at least a portion of a dose of TRC105 or sorafenib were included in the safety population. Both dose groups received 10 mg/kg TRC105 for the first month. Patients assigned to the 10 mg/kg weekly (cycle 1) then 15 mg/kg every two weeks (cycle 2+) dose group who discontinued the study prior to initiating cycle 2 dosing were counted in the 10 mg/kg weekly adverse event group.

Additional Information

Charles Theuer

TRACON Pharmaceuticals Inc.

Phone: (858) 550-0780

Email: ctheuer@traconpharma.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place